Nearly a quarter of a million children have acquired HIV, prompting the implementation of new protocols-Option B and B+-for treating HIV+ pregnant women. While efficacy has been demonstrated in randomized trials, there is limited real-world evidence on the impact of these changes.
Universal antiretroviral therapy (ART) for all pregnant/ breastfeeding women living with HIV, known as prevention of mother-to-child transmission of HIV (PMTCT) Option B+ (PMTCTB+), is being scaled up in most countries in Sub-Saharan Africa.
Lesotho's HIV prevalence among pregnant women is 28%. In 2013, Lesotho's Prevention of Mother to Child Transmission (PMTCT) program adopted Option B+ and revitalized the village health worker (VHW) program to strengthen community level PMTCT.
This study aimed to evaluate the impact of clinic-based prevention of mother-to-child transmission (PMTCT) community support by trained lay health workers in addition to standard clinical care on PMTCT infant outcomes.
In 2013, Uganda updated its prevention of maternal-to-child transmission of HIV program to Option B+, which requires that all HIV-infected pregnant and breastfeeding women be started on lifelong antiretroviral therapy (ART) regardless of CD4 count.
This qualitative study described experiences of participants in a randomized controlled trial that examined male partner recruitment strategies for couples HIV testing and counseling within an antenatal unit in Malawi.
Remarkable progress is being made on HIV treatment. Ahead of World AIDS Day, UNAIDS has launched a new report showing that access to treatment has risen significantly. In 2000, just 685 000 people living with HIV had access to antiretroviral therapy.
The Pediatric-Adolescent Treatment Africa (PATA) and the Positive Action for Children Fund (PACF) have worked across 9 countries and facilitated 36 clinic-community collaborations through their partnership on the three-year Clinic-CBO Collaboration (C3) Programme, which aims to strengt